Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:34:09.783Z.
Calculation as of: 2026-10-06T17:34:09.783Z.
Quote observation: 2026-10-06T17:30:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69957a8c264286ff6eaa706b48c8270e863bf40c8b9bfd4321b5f2d082882a11
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Sionna Therapeutics, Inc.
Market Cap
$205.31M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.60M
Price/OCF Ratio
N/A
TTM Avg
10.01
3Y Avg
10.01
5Y Avg
10.01
Market Cap
$206.91M
Price/OCF Ratio
N/A
TTM Avg
4.01
3Y Avg
4.01
5Y Avg
4.01
Market Cap
$206.12M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$211.22M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $205.31M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $205.20M | 28.34 | 26.60 | 21.85 | 26.58 |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $206.60M | N/A | 10.01 | 10.01 | 10.01 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $206.91M | N/A | 4.01 | 4.01 | 4.01 |
| Alector, Inc. (ALEC)vs › | $203.98M | N/A | 3.18 | 3.20 | 4.43 |
| Electra Therapeutics Inc. (ETRA)vs › | $206.12M | N/A | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $200.35M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.22M | N/A | N/A | N/A | N/A |
| Surrozen, Inc. (SRZN)vs › | $197.18M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
